About Beta Bionics, Inc.
https://www.betabionics.comBeta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
CEO
Sean T. Saint
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 71
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
EVENTIDE ASSET MANAGEMENT, LLC
Shares:4.96M
Value:$84.22M
FARALLON CAPITAL MANAGEMENT LLC
Shares:4.31M
Value:$73.29M
WELLINGTON MANAGEMENT GROUP LLP
Shares:3.9M
Value:$66.29M
Summary
Showing Top 3 of 129
About Beta Bionics, Inc.
https://www.betabionics.comBeta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $27.25M ▲ | $32.16M ▼ | $-14.21M ▲ | -52.14% ▲ | $-0.33 ▲ | $-13.53M ▲ |
| Q2-2025 | $23.24M ▲ | $32.38M ▲ | $-16.87M ▲ | -72.59% ▲ | $-0.39 ▲ | $-16.22M ▲ |
| Q1-2025 | $17.64M ▼ | $27.61M ▲ | $-28.66M ▼ | -162.46% ▼ | $-0.93 ▼ | $-18.04M ▼ |
| Q4-2024 | $20.44M ▲ | $24.73M ▲ | $-18.11M ▼ | -88.59% ▼ | $-0.42 ▲ | $-17.58M ▼ |
| Q3-2024 | $16.7M | $19.89M | $-9.74M | -58.28% | $-1.55 | $-10.67M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $228.69M ▼ | $330.05M ▲ | $35.29M ▲ | $294.76M ▼ |
| Q2-2025 | $249.72M ▲ | $329.97M ▼ | $28.34M ▲ | $301.63M ▼ |
| Q1-2025 | $231.47M ▲ | $338.02M ▲ | $24.27M ▼ | $313.75M ▲ |
| Q4-2024 | $103.58M ▲ | $149.65M ▲ | $73.63M ▲ | $76.01M ▲ |
| Q3-2024 | $60.9M | $96.94M | $64.07M | $32.87M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-14.21M ▲ | $-8.73M ▲ | $9.49M ▲ | $2.65M ▲ | $3.41M ▲ | $-10.01M ▲ |
| Q2-2025 | $-16.87M ▲ | $-13.59M ▲ | $6.17M ▲ | $42K ▼ | $-7.38M ▼ | $-15.37M ▲ |
| Q1-2025 | $-28.66M ▼ | $-19.98M ▼ | $-179.12M ▼ | $211.12M ▲ | $12.02M ▼ | $-20.31M ▼ |
| Q4-2024 | $-18.11M ▼ | $-14.28M ▼ | $-29.66M ▼ | $56.89M ▲ | $12.95M ▼ | $-14.84M ▼ |
| Q3-2024 | $-9.74M | $-9.61M | $15.24M | $-1.18M | $17.48M | $-11.53M |
CEO
Sean T. Saint
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 71
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
EVENTIDE ASSET MANAGEMENT, LLC
Shares:4.96M
Value:$84.22M
FARALLON CAPITAL MANAGEMENT LLC
Shares:4.31M
Value:$73.29M
WELLINGTON MANAGEMENT GROUP LLP
Shares:3.9M
Value:$66.29M
Summary
Showing Top 3 of 129